Regenerative platform Xeltis is developing transformative implants that enable the natural creation of living and long-lasting vessels, with a focus on restoring tissue and reducing need for traditional grafts in vascular procedures. This suggests sales opportunities in hospitals pursuing advanced regenerative medicine and dialysis access solutions.
Axxess hemodialysis The aXess vascular implant for hemodialysis access is advancing toward FDA approval and US market launch, with recent European commercial activity and first patient treatment in Germany. Targeted outreach can be directed at nephrology networks, dialysis centers, and reimbursement stakeholders in the US and EU.
Strategic funding Recent funding rounds totaling over €20 million with backing from Horizon 3 Healthcare, Invest-NL and other strategic investors indicate strong investor confidence and potential for scaled manufacturing, clinical trials, and market entry, offering openings for partner agreements or co-development opportunities.
European expansion Commercial activity expanding in Europe and ongoing lab development at High Tech Campus Eindhoven signal readiness for regional partnerships, distribution agreements, and local regulatory navigation services to accelerate time-to-market in European healthcare systems.
Clinical and KOL engagement Active participation in global events (LSX World Congress) and a high-level medical leadership team (CMO involvement) point to opportunities for advisory boards, clinical collaborations, and projected case-based selling to vascular surgeons and nephrologists.